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OBJECTIVE — The objective of this study was to determine the degree to which ramipril and/or
rosiglitazone changed -cell function over time among individuals with impaired fasting glucose
(IFG) and/or impaired glucose tolerance (IGT) who participated in the Diabetes Reduction Assess-
mentWithRamiprilandRosiglitazoneMedication(DREAM)Trial,whichevaluatedwhetherramipril
and/or rosiglitazone could prevent or delay type 2 diabetes in high-risk individuals.
RESEARCH DESIGN AND METHODS — The present analysis included subjects (n 
982) from DREAM trial centers in Canada who had oral glucose tolerance tests at baseline, after
2 years, and at the end of the study. -Cell function was assessed using the fasting proinsulin–
to–C-peptide ratio (PI/C) and the insulinogenic index (deﬁned as 30–0 min insulin/30–0 min
glucose) divided by homeostasis model assessment of insulin resistance (insulinogenic index
[IGI]/insulin resistance [IR]).
RESULTS — Subjects receiving rosiglitazone had a signiﬁcant increase in IGI/IR between
baseline and end of study compared with the placebo group (25.59 vs. 1.94, P  0.0001) and a
signiﬁcant decrease in PI/C (0.010 vs. 0.006, P  0.0001). In contrast, there were no
signiﬁcantchangesinIGI/IRorPI/Cinsubjectsreceivingramiprilcomparedwithplacebo(11.71
vs.18.15,P0.89,and0.007vs.0.008,P0.64,respectively).Theimpactofrosiglitazone
onIGI/IRandPI/CwassimilarwithinsubgroupsofisolatedIGTandIFGIGT(allP0.001).
Effects were more modest in those with isolated IFG (IGI/IR: 8.95 vs. 2.13, P  0.03; PI/C:
0.003 vs. 0.001, P  0.07).
CONCLUSIONS — Treatment with rosiglitazone, but not ramipril, resulted in signiﬁcant
improvements in measures of -cell function over time in pre-diabetic subjects. Although the
long-term sustainability of these improvements cannot be determined from the present study,
these ﬁndings demonstrate that the diabetes preventive effect of rosiglitazone was in part a
consequence of improved -cell function.
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P
ancreatic -cell dysfunction plays a
central role the pathogenesis of type
2diabetes(1).Itispresentinpeople
at high risk for type 2 diabetes, including
those with impaired fasting glucose (IFG)
and impaired glucose tolerance (IGT)
(2,3), and it predicts the development of
type 2 diabetes in prospective studies of
people with these disorders (4,5). -Cell
function is also known to decline steadily
over the course of type 2 diabetes, high-
lighting the progressive nature of this
disorder (6). It is therefore crucial to un-
derstandthefactorsthaterodeorpreserve
-cell function across the spectrum of
glucose tolerance. Relatively little infor-
mation is available, however, regarding
the determinants of -cell dysfunction in
humans (1).
Recent evidence suggests that thiazo-
lidinediones (TZDs) and ACE inhibitors
may preserve -cell function (7,8). Al-
though TZDs have been demonstrated to
improve glucose control and -cell func-
tion in type 2 diabetes (9–11), very little
is known about the effect of TZDs on
-cell function in people with hypergly-
cemia in the nondiabetic range, namely
those with IGT and/or IFG (12–15). Sim-
ilarly, while it has been hypothesized that
ACE inhibitors may lower glucose via di-
recteffectsonthe-cell(16),studieshave
not been conducted in people with IGT
and/or IFG.
The objectives of this study, there-
fore, were to determine the degree to
which ramipril (an ACE inhibitor) and/or
rosiglitazone (a TZD) changed -cell
function over time among individuals
with IFG and/or IGT who participated in
the Diabetes Reduction Assessment With
Ramipril and Rosiglitazone Medication
(DREAM) Trial, which evaluated whether
ramipril and/or rosiglitazone could pre-
vent or delay diabetes in high-risk indi-
viduals. We also aimed to determine the
degree to which changes in indexes of
-cell function over time were modiﬁed
by baseline glucose tolerance status and
whether ramipril and/or rosiglitazone’s
effectondiabetesincidencewasmediated
by treatment-induced changes in -cell
function.
RESEARCH DESIGN AND
METHODS— The design and princi-
palﬁndingsoftheDREAMtrialhavebeen
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Nutritional Sciences, University of Toronto, Toronto, Canada; the
2Leadership
Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada; the
3Division of Endocrinology,
Department of Medicine, University of Toronto, Toronto, Canada; and the
4Division of Endocrinology
and Metabolism and the Population Health Research Institute, Department of Medicine, McMaster Uni-
versity and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Corresponding author: Anthony Hanley, anthony.hanley@utoronto.ca.
Received 24 August 2009 and accepted 8 December 2009. Published ahead of print at http://care.
diabetesjournals.org on 15 December 2009. DOI: 10.2337/dc09-1579.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
608 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgpresented in previous publications (17).
Brieﬂy, the DREAM trial was a large, in-
ternational, multicenter, double-blind,
randomized controlled trial designed to
determine whether ramipril and/or ros-
iglitazone could prevent or delay the de-
velopment of type 2 diabetes in people
with IFG or IGT, metabolic states that in-
dicate very high risk for eventual progres-
sion to diabetes (17). Eligibility for the
DREAM trial included a diagnosis of IFG,
IGT, or both IFG and IGT based on a
screening 75-g oral glucose tolerance test
(OGTT)(17).Atotalof5,269participants
with these disorders were recruited and
randomized to either ramipril and/or ros-
iglitazone using a two-by-two factorial
design and followed for a median of 3
years after randomization. Participants
wereassessedatregularintervalstoascer-
tain the occurrence of the primary
outcome, which included new-onset dia-
betes or all-cause mortality. As part of a
substudy, 982 DREAM trial participants
attending Canadian study centers had
OGTTs at baseline, after 2 years, and at
the end of the study, with blood samples
drawn fasting as well as 30 and 120 min
after the glucose challenge.
The primary outcome variable in the
present study was change in -cell func-
tion over the course of follow-up. -Cell
function was assessed using two mea-
sures: the insulinogenic index (IGI) and
proinsulin (PI) concentration, with IGI
deﬁned as (30-min insulin  fasting in-
sulin)/(30-min glucose  fasting glu-
cose). Both indexes have previously been
validated against gold-standard measures
ofinsulinsecretion(18,19)andhavebeen
shown to be signiﬁcant predictors of inci-
dent diabetes in large epidemiological
studies. To account for the compensatory
responseofinsulinsecretioninrelationto
background insulin resistance, IGI was
divided by the homeostasis model assess-
ment of insulin resistance index (HOMA-
IR) (deﬁned as fasting glucose  fasting
insulin/22.5 [20]) (IGI/IR) for univariate
analysisoradjustedforHOMA-IRinmul-
tivariate analysis. Similarly, PI con-
centration was divided by C-peptide con-
centration(i.e.,thePI/C-peptideratio[PI/
C]) for univariate analysis or adjusted for
insulin secretion using C-peptide as a co-
variate in multivariate analysis. Although
the PI-to-insulin ratio is often used to
identify disproportionate elevations in PI,
C-peptide offers advantages over insulin
as a denominator for PI because it is cose-
creted with insulin in an equimolar ratio,
butunlikeinsulinitisnotextractedbythe
liver and thus it has a constant peripheral
clearance.
Glucose concentration was deter-
mined using an enzymatic reference
method on a Roche Hitachi 917 Instru-
ment and a Roche reagent kit (Roche Di-
agnostics, Indianapolis, IN). Serum
insulin and C-peptide were measured on
theRocheElecsys2010immunoassayan-
alyzer using an electrochemilumines-
cence immunoassay. The insulin assay
had a sensitivity of 1.39 pmol/l, an inter-
assay coefﬁcient of variation (CV) of
4.6% at all levels, and 0.05% cross-
reactivity with human C-peptide and PI.
The C-peptide assay had a sensitivity of
3.0pmol/l,aninterassayCVof3%atall
levels,and0.005%cross-reactivitywith
human insulin. PI concentration was
measured using a sandwich enzyme-
linked immunosorbent assay manufac-
tured by Linco Research (Linco Research,
St. Charles, MO). This assay had a sensi-
tivity of 2.0 pmol/l, an interassay CV of
9% at all levels, and no cross-reactivity
with human insulin or des (31,32) split
PI, although this assay does cross-react
with human des (64,65) split PI.
Statistical analysis
Statistical analyses were conducted using
SASversion9.1(SASInstitute,Cary,NC),
and P values 0.05 were considered sta-
tistically signiﬁcant. The distributions of
continuous variables were assessed for
normality,andtransformationsofskewed
variables were used in the analysis as ap-
propriate. Means and SDs for primary
-cell function measures (IGI/IR and
PI/C) were calculated for each time point
(baseline, at 2 years, and ﬁnal visit), ac-
cording to the marginal treatment group.
Change was calculated as baseline minus
ﬁnal visit value. P values for change were
based on a t test of the average change
being different from zero, while P values
for treatment difference were calculated
using the Wilcoxon’s rank-sum test. Sim-
ilar analyses were conducted within sub-
groups of isolated IFG (IIFG), isolated
IGT (IIGT), and combined IFG and IGT
(IFGIGT). As there was no signiﬁcant
interaction between ramipril and ro-
siglitazone’s effect on -cell function,
main-effects analyses were conducted ac-
cording to marginal randomization
groups (i.e., rosiglitazone versus placebo,
ramipril versus placebo).
Longitudinal analyses of the associa-
tions between treatments and changes
over time in -cell function measures
were examined using random-effects
models in PROC MIXED, which pro-
vides appropriate options for handling
the covariance structure of the repeat-
ed-measures(longitudinal)data.Specif-
ically,weranfourmodels,whichassessed
the impact of treatment group on 1) IGI,
with age and HOMA-IR as covariates; 2)
IGI/HOMA-IR, with age as a covariate; 3)
PI, with age and C-peptide as covariates;
and 4) PI/C, with age as a covariate.
Finally, using Cox proportional haz-
ards regression, we assessed whether the
impact of ramipril and/or rosiglitazone
treatmentondiabetesincidencewasinde-
pendent of baseline levels and changes
over the course of the trial in -cell func-
tion. The outcome variable in these anal-
yses was diabetes status at the ﬁnal visit,
and the primary exposures were the mar-
ginal treatment groups (rosiglitazone,
ramipril).Inseparatemodels,weassessed
the impact of treatment on diabetes inci-
dence, adjusting for either baseline -cell
function (including baseline IGI and
HOMA-IRorbaselinePIandC-peptideas
covariates) or change over the course of
the trial in -cell function (including
changes in the above-mentioned covari-
ates). Baseline models were also adjusted
for age and baseline waist circumference,
fasting glucose, triglycerides, and HDL,
while change models were also adjusted
for age and changes in these covariates.
RESULTS— Baselinecharacteristicsof
participants in this DREAM substudy are
presentedinTable1.Theaverageageand
BMI were 54 years and 31.5 kg/m
2,r e -
spectively, and 60% of participants were
female. The majority (81%) were of Eu-
ropean origin, and substantial propor-
tions had a family history of diabetes or
a history of gestational diabetes (61 and
16%, respectively), characteristics that
were consistent with the recruiting
strategyfortheDREAMtrial(17).There
were no signiﬁcant differences between
the marginal randomization groups for
any of the baseline characteristics other
than family history of diabetes in the
ramipril versus placebo marginal group
(P  0.02) (Table 1).
Changesinmarkersof-cellfunction
in marginal randomization groups are
presented in Table 2. Participants receiv-
ingrosiglitazoneversusplacebohadasig-
niﬁcant increase in IGI/IR during the
study (25.59 vs. 1.94, P  0.0001) and a
signiﬁcant decrease in PI/C (0.010 vs.
0.006, P  0.0001). In contrast, there
were no signiﬁcant changes in IGI/IR or
PI/C in participants receiving ramipril
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0.05, and 0.007 vs. 0.008, P  0.05,
respectively) (Table 2). In the rosiglita-
zone group, changes in the -cell func-
tion measures were more substantial
between the baseline and 2-year visits
compared with changes that occurred be-
tweenthe2-yearandﬁnalvisits(Table2).
The impact of rosiglitazone on IGI/IR and
PI/CwassimilarwithinsubgroupsofIIGT
and IFG  IGT (IIGT, IGI/IR: 27.74 vs.
2.76, P  0.0001; PI/C: 0.009 vs.
0.008, P  0.001; IFG  IGT, IGI/IR:
27.39 vs. 0.70, P  0.0001; PI/C:
0.014 vs. 0.002, P  0.0001), al-
though effects were more modest in those
with IIFG (IGI/IR: 8.95 vs. 2.13, P 
0.03;PI/C:0.003vs.0.001,P0.05)
(supplemental Table, available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1579/DC1).
We further assessed the impact of
treatment on markers of -cell function
by utilizing longitudinal data from multi-
ple study time points in mixed-model
analyses.Comparedwithplacebo,rosigli-
tazonesigniﬁcantlyincreasedIGIafterad-
justment for age and HOMA-IR (P 
0.015) (Table 3). In contrast, ramipril did
not signiﬁcantly affect adjusted IGI (P 
0.05). Similar ﬁndings were seen using PI
concentrationasameasureof-cellfunc-
tion. Speciﬁcally, rosiglitazone signiﬁ-
cantly reduced PI concentrations over
time after adjustment for age and C-
peptide concentration (P  0.0064) (Ta-
ble 3). In contrast, ramipril did not
signiﬁcantly change adjusted PI concen-
trations (P  0.05).
We assessed whether the impact of
ramipril and/or rosiglitazone on diabetes
incidence was independent of baseline
levels or changes in indexes of -cell
functionwithtime(Fig.1).Afteraccount-
ing for baseline -cell function as mea-
sured by either IGI or PI in models that
adjusted for insulin resistance and other
covariates, rosiglitazone signiﬁcantly re-
duced the risk of developing diabetes
(hazard ratio 0.32 [95% CI 0.22–0.45],
P  0.001, and 0.33 [0.23–0.47], P 
0.001, in IGI and PI models, respec-
tively). Adjusting for the change in -cell
function as measured by IGI attenuated
the preventive effect of rosiglitazone on
incident diabetes (0.53 [0.28–0.99], P 
0.046). Such attenuation was not noted
when the change in -cell was measured
using PI (0.28 [0.18–0.42], P  0.0001)
(Fig. 1, model 2). Ramipril showed
smaller, nonsigniﬁcant reductions in dia-
betes risk.
CONCLUSIONS — Rosiglitazone, but
notramipril,improvedmeasuresof-cell
function over time in people with IFG
and/or IGT. Speciﬁcally, rosiglitazone in-
creased IGI/IR and reduced PI/C by 86
and 42%, respectively. These ﬁndings
were consistent across glucose tolerance
subgroups (IIFG, IIGT, and IFGIGT),
although there was the suggestion of a
more modest effect in the subgroup with
IIFG. Finally, rosiglitazone’s effect on di-
abetes prevention persisted after adjust-
Table 1—Baseline characteristics of participants with measures of -cell function overall and by allocation
Overall
Randomization (marginal groups)
Rosiglitazone Placebo Ramipril Placebo
n 982 505 477 494 488
Age (years) 54.36  10.64 54.81  10.49 53.9  10.79 53.96  10.47 54.77  10.81
BMI (kg/m
2) 31.49  5.45 31.36  5.33 31.63  5.58 31.25  5.35 31.74  5.54
Waist-to-hip ratio 0.89  0.09 0.89  0.09 0.9  0.09 0.89  0.09 0.9  0.09
Systolic blood pressure
(mmHg) 135.07  16.85 135.4  15.92 134.71  17.79 134.75  16.52 135.39  17.18
Diastolic blood pressure
(mmHg) 82.79  9.89 82.88  9.5 82.69  10.29 82.57  10.06 83  9.72
Females 593 (60.39) 298 (59.01) 295 (61.84) 297 (60.12) 296 (60.66)
IIFG 97 (9.88) 49 (9.7) 48 (10.06) 49 (9.92) 48 (9.84)
IIGT 609 (62.02) 312 (61.78) 297 (62.26) 310 (62.75) 299 (61.27)
IFG and IGT 276 (28.11) 144 (28.51) 132 (27.67) 135 (27.33) 141 (28.89)
Gestational diabetes 93 (15.68) 52 (17.45) 41 (13.9) 51 (17.17) 42 (14.19)
Family history diabetes 597 (60.79) 296 (58.61) 301 (63.1) 318 (64.37) 279 (57.17)
European 795 (80.96) 416 (82.38) 379 (79.45) 400 (80.97) 395 (80.94)
Other ethnicity 187 (19.04) 89 (17.62) 98 (20.55) 94 (19.03) 93 (19.06)
Statin 56 (15.89) 77 (15.25) 79 (16.56) 73 (14.78) 83 (17.01)
Blood pressure medications 168 (17.11) 93 (18.42) 75 (15.72) 82 (16.6) 86 (17.62)
Fasting glucose (mmol/l) 5.76  0.66 5.77  0.66 5.74  0.67 5.75  0.66 5.77  0.67
30-min glucose (mmol/l) 10.45  1.74 10.55  1.74 10.35  1.73 10.41  1.74 10.5  1.74
2-h glucose (mmol/l) 8.78  1.35 8.8  1.29 8.76  1.4 8.74  1.36 8.82  1.33
Fasting insulin (pmol/l) 88.92  2.67 88.36  2.66 89.52  2.67* 86.5  2.61 91.43  2.72*
30-min insulin (pmol/l) 438.44  3.53 435.11  3.44 442.0  3.63* 436.31  3.51 440.6  3.55*
IGI 78.38  2.93 75.78  2.99 81.22  2.86* 79.8  2.82 76.97  3.04*
IGI/IR 30.56  22.78 29.43  20.26 31.75  25.16 31.52  23.18 29.59  22.36
Fasting PI (pmol/l) 13.47  1.92 13.56  1.93 13.37  1.91* 13.13  1.9 13.82  1.94*
Fasting C-peptide (pmol/l) 1,011.32  454.96 1,005.15  450.93 1,017.84  459.56 999.98  452.87 1,022.82  457.24
PI/C 0.02  2.98 0.02  3.01 0.02  2.94* 0.02  2.99 0.02  2.97*
Data are means  SD or n (%). No signiﬁcant differences between rosiglitazone versus placebo or ramipril versus placebo other than family history of diabetes in the
ramipril versus placebo group (P  0.02). *Indicates that statistical testing was performed using geometric means.
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demonstration that an agent that reduces
diabetes incidence also improves -cell
function invites the hypothesis that mea-
sures of change in -cell function in re-
sponse to therapy are indexes of that
therapy’s ability to reduce the incidence
of diabetes. The modest attenuation of
rosiglitazone’s effect after accounting for
thechangein-cellfunctionsuggeststhat
some but not all of the effect of rosiglita-
zone on diabetes prevention/delay is me-
diated through its effects on -cell
function.
Whereas a number of previous stud-
ies (9–11) have documented improve-
ments in -cell function with TZD
treatment in people with diabetes, only
four studies (12–15) have investigated
this question in people with IFG and/or
IGT. The results of these studies have
been inconsistent, with two studies
(12,15) indicating a signiﬁcant improve-
ment in measures of -cell function with
TZD treatment and two studies (13,14)
reportingnochange.Thesestudiesallhad
small sample sizes (n  30), and the
methods used to assess -cell function
varied widely from intensive approaches
(insulin responses to glucose infusion
[12,14]) to simple fasting-based indexes
(HOMA-B [13,15]). Interestingly, the
complexity of the method used to assess
-cell function did not appear to explain
the differences in ﬁndings of these previ-
ous studies (12,14). Finally, in a diabetes
prevention trial among Hispanic women
withpreviousgestationaldiabetes,	70%
of whom had IGT at enrollment, treat-
ment with troglitazone resulted in signif-
icant improvements in the frequently
Table 2—Changes in markers of -cell function
Study visit

(Ins30–Ins0)/(Gluc30–Gluc0)/HOMA-IR PI/C
nPMeans  SD nPMeans  SD
A: rosiglitazone marginal group
Placebo Baseline 357 34.0  22.82 449 0.022  0.04
2 years 350 41.74  43.94 422 0.019  0.03
Final 357 35.94  38.42 449 0.016  0.02
Change* 357 1.94  36.37 449 0.006  0.04
P† 0.31 0.0044
Rosiglitazone Baseline 429 29.95  20.44 480 0.024  0.04
2 years 417 59.82  82.93 463 0.018  0.03
Final 429 55.53  125.14 480 0.014  0.02
Change* 429 25.59  125.22 480 0.010  0.04
P† 0.0001 0.0001
Treatment difference P‡ 0.0001 0.0001
B: ramipril marginal group
Placebo Baseline 383 30.72  21.17 461 0.023  0.04
2 years 372 50.26  72.91 440 0.017  0.02
Final 383 48.87  128.97 461 0.014  0.01
Change* 383 18.15  128.93 461 0.008  0.04
P† 0.0062 0.0001
Ramipril Baseline 403 32.80  22.04 468 0.023  0.04
2 years 395 52.80  64.20 445 0.020  0.04
Final 403 44.51  48.48 468 0.015  0.03
Change* 403 11.71  48.18 468 0.007  0.05
P† 0.0001 0.0009
Treatment difference P‡ 0.89 0.64
Data are means  SD and are reported for marginal treatment groups. *Change was calculated as baseline minus ﬁnal visit value. †P value for change were based
on a t test of the average change being different from zero. ‡P values for treatment difference were calculated using the Wilcoxon rank-sum test.
Table 3—Longitudinal changes in markers of -cell function in DREAM trial: analysis of
slopes using mixed-model analysis
Slope SE P
Slope
difference
Rosiglitazone versus placebo
PI
PI/C (adjusted for age) 0.003 0.0005 0.25 0.0008
PI (adjusted for age, fasting C-peptide) 1.0524 0.1344 0.0064 0.5308
IGI
IGI/HOMA-IR (adjusted for age) 9.0674 1.115 0.0001 7.0191
IGI (adjusted for age and HOMA-IR) 5.2814 1.3232 0.015 4.7305
Ramipril versus placebo
PI
PI/C (adjusted for age) 0.0028 0.0005 0.57 0.0004
PI (adjusted for age, fasting C-peptide) 0.7796 0.14 0.87 0.0329
IGI
IGI/HOMA-IR (adjusted for age) 5.2084 1.1522 0.5 1.1206
IGI (adjusted for age and HOMA-IR) 2.7603 1.3517 0.73 0.6681
Analysisintablearebasedonfulldata;resultsessentiallyunchangedwhenanalysisrepeatedonsubjectswith
information from all visits.
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determined disposition index after 3
months (21).
Our results suggest a signiﬁcant im-
provement in -cell function with TZD
treatment in pre-diabetic subjects. These
ﬁndingsextendtheliteratureinanumber
of important ways. First, the sample size
of our study (n  982) was much larger
that previous investigations. Second, we
demonstrated improvements in -cell
function under TZD treatment using two
validated, widely used proxy measures of
-cellfunction,namelyIGIandPI.Third,
in our analysis we accounted for the com-
pensatory impact on -cell function of
background insulin resistance. Speciﬁcally,
in analyses of IGI we used HOMA-IR ei-
ther as a covariate in multivariate analysis
or as the denominator in the IGI–to–
HOMA-IR ratio. C-peptide was used in a
similarfashioninanalysesofPI.Account-
ing for background insulin resistance is
crucial to the interpretation of -cell
function measures in this study because
TZDs improved insulin sensitivity, thus
reducing pancreatic -cell demand.
The exact mechanisms responsible
for the increases in IGI/IR and the reduc-
tions in PI/C documented in the present
study are not known, although a number
of possibilities exist. The reduction in in-
sulin resistance with TZDs would be
expected to reduce insulin secretory de-
mand on the -cells and thus reduce
-cell stress. In addition, TZDs such as
rosiglitazone may improve -cell func-
tion indirectly by ameliorating a number
of pathogenic processes that have been
shown to be detrimental to the -cells,
including lipotoxicity, glucotoxicity, and
inﬂammation (7,8). TZDs lower free fatty
acids (22), elevated levels of which result
in excess deposition of lipid within
-cells,whichinturnleadstoincreasesin
ceremide and the stimulation of nitric ox-
ide–mediated -cell apoptosis. As well,
the glucose-lowering effect of TZDs may
reduce the impact of reactive oxygen spe-
ciesonthe-cells,whichareknowntobe
especially susceptible to oxidative dam-
age(23).Finally,TZDshavebeendemon-
strated to reduce levels of inﬂammatory
cytokines (24), which may induce -cell
apoptosis when chronically elevated.
TZDs may also impact -cell function di-
rectly by maintaining -cell proliferation
and/or reducing -cell apoptosis (25).
In the HOPE study, treatment with
ramipril was shown to reduce the inci-
dence of diabetes in middle-aged individ-
uals with vascular disease. In the DREAM
trial, although ramipril did not signiﬁ-
cantly reduce the incidence of diabetes in
people with IFG and/or IGT, it did signif-
icantly increase regression to normogly-
cemia. The mechanism by which ramipril
mightreduceglucoselevelsand/orprevent/
delaydiabetesisunknown,althoughvascu-
lar and metabolic effects on the muscle and
pancreatic -cell have been proposed (16).
Theresultsofthepresentstudysuggestthat
ramipril does not have signiﬁcant effects on
-cell function compared with placebo in
people at high risk for diabetes, and thus its
glucose-lowering effects may operate
through other metabolic mechanisms. The
improvement in -cell function in the pla-
cebo arm of the ramipril marginal group
analysis may be explained by the fact that
under the factorial design of the DREAM
trial,halfoftheparticipantsonramiprilpla-
cebo were receiving active rosiglitazone.
The major strengths of the present
study include the large sample size, the
randomized, double-blind design, and
the completeness of follow-up (92.6%).
Further, participants were thoroughly
characterized in terms of glucose toler-
ance status and were all in the pre-
diabetic range (either IIFG, IIGT, or
IFGIGT). The major limitation of the
present study is the lack of detailed mea-
sures of -cell function, such as those ob-
tained from the hyperglycemic clamp
technique or the frequently sampled in-
travenous glucose tolerance test. Not-
withstanding, we used two proxy
measures of -cell function that have
been extensively validated and used in
previous studies including the Diabetes
Prevention Program and the American
Diabetes Association Genetics of Type 2
Diabetes Study (in the case of IGI/IR) and
the IRAS study (in the case of PI).
In conclusion, rosiglitazone, but not
ramipril, resulted in signiﬁcant improve-
ments in measures of -cell function over
time. These ﬁndings demonstrate that the
diabetes preventive effect of rosiglitazone
mayinpartbeaconsequenceofimproved
-cell function.
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Figure 1—Association of treatment allocation with risk of diabetes: impact of baseline levels and
changesin-cellfunction.
1ForIGI/IRmodels:model1adjustedforageandbaselineIGI,HOMA-
IR, fasting glucose, waist circumference, triglyceride, and HDL; model 2 adjusted for age and
changesinIGI,HOMA-IR,fastingglucose,waistcircumference,triglyceride,andHDL.
2ForPI/C
models: model 1 adjusted for age and baseline PI, C-peptide, fasting glucose, waist circumference,
triglyceride, and HDL; model 2 adjusted for age and changes in PI, C-peptide, fasting glucose,
waist circumference, triglyceride, and HDL.
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